We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Creo Medical Group Plc | CREO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 36.25 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 36.25 | 36.25 | 36.25 | 36.25 | 36.25 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 24/4/2024 08:33 by wan To repeat from a previous post 593 -As Edison's recent update noted: should the collaboration roll-over to include Intuitive's da Vinci systems (installed base of 8,606 systems), the market opportunity can be materially larger. We note that Creo is entitled to milestone and royalty payments as part of the collaboration (c £1.8m licensing fee in 2023). We view this as an exciting development and await further updates from the company. And a recent update re Intuitive - Published April 23, 2024 Intuitive’s da Vinci 5 robot could widen ‘already substantial’ lead: analysts Truist Securities analysts wrote that Medtronic and Johnson & Johnson could “be relegated to niche players” in surgical robotics. Dive Brief: The reaction of general surgeons to Intuitive Surgical’s da Vinci 5 has reinforced Truist Securities analysts’ belief the new surgical robot will widen the company’s “already substantial technology lead.” Full story - Creo's long-term, multi-year collaboration agreement with Intuitive to optimise certain Creo products to be compatible with Intuitive’s robotic technology, could make Intuitive's leading position almost untouchable! |
Posted at 04/3/2024 14:57 by someuwin New Edison Update:Creo Medical Clinical update MicroBlate Flex progresses with first robotics use Creo Medical has marked another milestone in advancing utility of its electrosurgical devices with the first use of its MicroBlate Flex device in a robotic-guided lung tissue ablation procedure (as part of an ongoing clinical study). Although not disclosed by the company, we believe this procedure was performed on Creo’s Kamaptive technology partner Intuitive Surgical’s ION bronchoscopy-focused robotics platform. Proving and expanding compatibility with robotic platforms has been an overarching goal for Creo and we see this as a notable step towards achieving this. The successful procedure also bodes well for the company’s partnership with Intuitive Surgical, which holds an estimated 57% market share in robotic surgical systems and has an installed base of 534 ION systems, indicative of the sizeable market opportunity for Creo. For reference the lung cancer therapeutic market size is estimated at $28bn in 2022 and is expected to reach c $60bn by 2032. MicroBlate Flex is a flexible, small diameter microwave ablation device designed for minimally-invasive soft tissue ablation. The device received FDA 510(k) clearance in 2021 (CE mark received in 2020) and is currently being evaluated for safety and feasibility in the treatment of lung lesions as part of a muti-site, post-market clinical study (announced in March 2023). The first-in-human procedure was performed in May 2023 by principal investigator, Professor Pallav L Shah, at the Royal Brompton Hospital in London, and this latest update marks the first robotics-assisted procedure using MicroBlate Flex. The procedure was used to ablate a 27mm cancerous nodule from a patient’s lung, in less than three minutes. Robotics-assisted procedures are a coveted goal in cancer treatment, given the greater precision rates and ability to excise small and hard-to-reach nodules and tumours using minimally invasive methods, greatly improving recovery rates and reducing hospitalisation expenses. The said procedure using MicroBlate Flex was performed in the same sitting as a diagnostic procedure, highlighting the utility of such systems in developing more efficient patient care and improving outcomes. We believe the procedure was conducted using Creo’s Kamaptive technology partner Intuitive Surgical’s ION robotics platform, with an installed base of 534 robots (including at the Royal Brompton Hospital) and 54,000 procedures conducted in 2023. Creo signed a multi-year collaboration with Intuitive Surgical in May 2022 and MicroBlate Flex’s utility with the ION robotics system appears to be the first of potential additional collaborations. Should the collaboration roll-over to include Intuitive’s da Vinci systems (installed base of 8,606 systems), the market opportunity can be materially larger. We note that Creo is entitled to milestone and royalty payments as part of the collaboration (c £1.8m licensing fee in 2023). We view this as an exciting development and await further updates from the company. |
Posted at 01/3/2024 07:21 by someuwin Creo Medical Group plc("Creo" the "Company" or the "Group") Microwave Lung Ablation Update Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces progress with its MicroBlate Flex device. Professor Pallav Shah and Dr Christopher Orton, of the Royal Brompton Hospital, have become the first specialists in the world to perform a robotic guided microwave ablation of lung tissue in the same sitting as a diagnostic procedure. Creo's MicroBlate Flex device was used to perform the procedure. In a recent announcement, Professor Shah and his team reported that microwave ablation was used to ablate a 27mm cancerous nodule in a patient's lung. The procedure took place at the Royal Brompton Hospital in London and is reported to have taken 3 minutes. Dr Orton commented: "The potential to combine the diagnosis, staging and treatment of lung cancer in one procedure offers significant benefit to patients." Link: Craig Gulliford, Chief Executive Officer of Creo, said: "Creo has been pioneering minimally invasive surgical endoscopy for pre-cancer and cancer patients for years, and implementing our technology into robotic application is a key goal for us as the adoption of this technology continues to grow exponentially. "We are incredibly proud that our MicroBlate Flex technology has been able to make this world-first possible. The potential for these technologies to combine precise robotically guided lung cancer diagnosis with the ablation of cancerous tissue in one session is transformational. Not only could this dramatically improve outcomes for lung cancer patients, but it has the potential to do away with long and worrying delays between diagnosis and treatment. This is the beginning of an exciting program and the team have done a terrific job in reaching this point." |
Posted at 25/1/2024 16:00 by wan As a reminder and for those who are relatively new -Released: 23/05/2022 Collaboration agreement with Intuitive Creo technology to be adapted for use with robotic-assisted surgical platform Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has signed a long-term, multi-year collaboration agreement (the "Agreement") with Intuitive to optimise certain Creo products to be compatible with Intuitive's robotic technology. Intuitive (Nasdaq: ISRG) is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Full Creo release - |
Posted at 10/1/2024 10:15 by wan Indeed more good news as Speedboats use gathers momentum across a range of clinical applications.Taking the last paragraph of todays RNS in isolation - Craig Gulliford, Chief Executive Officer of Creo Medical, said: "The procedures done at IECED have shown the full potential of the new Speedboat UltraSlim. We were thrilled to witness the successful execution of the F-POEM procedure using solely the Speedboat device, a task that traditionally requires three separate instruments. This not only showcases the device's efficiency but also enhances the cost-effectiveness of the procedure, underscoring the economic advantages Creo's technology can deliver to our valued customers." (END) Reducing the use of three instruments is excellent news for patients and hospitals, but it's also disruptive to the company/companies supplying the three instruments that will likely become somewhat redundant! It would thus be interesting to learn who those companies are, but in any regard its relatively easy to understand the continued attractions of licensing, strategically partnering, or deepening/extending existing agreements with Creo. Not to mention Creo's own clear pipeline and strategy to enhance each one of their revenue streams, all leading to an increasingly positive outlook for Creo! |
Posted at 15/12/2023 07:06 by someuwin 15 December 2023Creo Medical Group plc ("Creo" the "Company" or the "Group") First use of Speedboat(R) UltraSlim in the USA Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that its latest device, Speedboat(R) UltraSlim, has now been successfully used in the USA. The limited market release of the Speedboat(R) UltraSlim in the USA has resulted in the device being successfully used in multiple clinical applications. The first was a Speedboat Submucosal Dissection (SSD) in the colon for a precancerous lesion, followed by a precancerous resection in the oesophagus. Additional successful indications were Upper Oesophageal Peroral Endoscopic Myotomy and Zenkers Diverticulum, treating swallowing disorders and gastroparesis. These procedures come shortly after the Company announced that it had obtained 510(k) clearance from the US Food & Drug Administration for Speedboat(R) UltraSlim in November 2023 and follows the first UK case earlier this week. Speedboat(R) UltraSlim is the third device in Creo's Speedboat(R) family of products, and is targeting the therapeutic treatment of disease in the GI tract (including cancer of the Bowel, Stomach and Oesophagus) as well as surgical procedures to deal with abnormalities resulting in swallowing disorders and, in some cases, gastric reflux. This latest generation Speedboat has broad application in the GI tract due to a smaller configuration, ensuring compatibility with a wide range of colonoscopes and gastroscopes. Powered by Creo's CROMA advanced energy platform, Speedboat(R) UltraSlim delivers fluid as well as advanced bipolar radiofrequency ("RF") energy for controlled cutting and high frequency microwave ("MW") energy for controlled coagulation of tissue in the GI tract. The device is the culmination of a long programme of work to further miniaturise Creo's technology, and is compatible with the working channel of all commercially available endoscopes accessing the vast majority of GI endoscopic procedures. Craig Gulliford, Chief Executive Officer of Creo Medical, said: "Following the completion of the design transfer to manufacturing last week, the whole team has worked tirelessly to get Speedboat UltraSlim into the hands of clinicians. Having first use in the UK and the USA in a single week, not only validates the utility of our cutting edge technology, but succinctly illustrates the cohesion across our team and joint intention to deliver on our objectives. "Knowing the potential that having a device that is compatible with all major endoscopes brings, we are energised to get the device into the hands of clinicans to allow them to treat their patients, for more indications and improve lives. With significant demand for this product already indicated from existing and potential Speedboat users , we will continue our early market release ahead of the full market launch in early 2024. " Continued innovation of the Speedboat platform with smaller multi-modal devices supports the continued evolution of minimally invasive procedures that deliver better clinical and economic outcomes for the healthcare community and their patients." |
Posted at 13/12/2023 07:14 by someuwin 13 December 2023Creo Medical Group plc ("Creo" the "Company" or the "Group") First European Speedboat(R) UltraSlim procedure marks early commercial launch Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces the initiation of its commercial launch of Speedboat(R) UltraSlim, following the completion of the design transfer to manufacturing last week. The first procedure using the device was completed in the UK. This first use of Speedboat(R) UltraSlim was for a lower Gastrointestinal ("GI") tract procedure, and comes shortly after the Company announced the UK and EU regulatory pathway had been accelerated by approximately 18 months . The Company expects the first European upper GI cases to follow soon, as well as first upper and lower GI cases in the USA, following the 510(k) clearance being received from the US Food & Drug Administration in November 2023. Speedboat(R) UltraSlim is the third device in Creo's Speedboat(R) family of products. The device is the culmination of a long programme of work to miniaturise the technology to a scale which covers all the foreseeable market applications, resulting in blanket compatibility with all commercial endoscopes accessing the vast majority of GI endoscopic procedures and significantly increasing the opportunity for more clinicians and patients to benefit from Creo's cutting-edge technology. Speedboat(R) UltraSlim is targeting the therapeutic treatment of disease in the GI tract including cancer of the Bowel, Stomach and Oesophagus as well as surgical procedures to deal with abnormalities resulting in swallowing disorders and in some cases gastric reflux. Powered by Creo's CROMA advanced energy platform, Speedboat(R) UltraSlim delivers advanced bipolar radiofrequency ("RF") energy for controlled cutting and high frequency microwave ("MW") energy for controlled coagulation of tissue in the GI tract. Craig Gulliford, Chief Executive Officer of Creo Medical, said: " This is yet another landmark moment for Creo Medical. We know what a difference this even smaller device will make in terms of broadening access to advanced energy in endoscopy for a wider pool of clinicians. Speedboat UltraSlim is compatible with all major endoscopes, meaning clinicians can bring advanced energy to their practices, allowing more patients to be treated endoscopically, which avoids surgery and the associated secondary costs and risks. We will continue the early market release to a designated early adopter programme over the coming weeks before the full market launch in early 2024, with significant demand for this product already indicated from existing and potential Speedboat users ." |
Posted at 12/10/2023 10:36 by xxxxxy Creo Medical Group PLC Investor PresentationSource: |
Posted at 16/8/2023 07:10 by someuwin 16 August 2023Creo Medical Group plc ("Creo" the "Company" or the "Group") Royal Oldham SSD service going from strength to strength 40 cases completed in record time, with patients and waiting lists experiencing immediate benefits Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, provides an update on the implementation of its technology within The Royal Oldham Hospital ("Royal Oldham"). On 17 May, Creo announced that Royal Oldham had become the first NHS hospital to immediately implement CROMA and Speedboat(TM) Inject across multiple endoscopy rooms, putting in place weekly lists for multiple SSD (Speedboat Submucosal Dissection) cases. The hospital has now treated over 40 patients using the new service, representing the fastest time for any NHS hospital to reach the landmark, with exceptional results for patients, the hospital and its staff. Multiple doctors at the hospital have already progressed through Creo's Pioneer Programme mentoring stage and are independently treating regular lists of patients presenting with complex, high-risk lesions in the colon. Creo has a target base for the Speedboat range of products of more than 350 NHS hospitals, with each SSD procedure demonstrated to save the NHS up to GBP10k when compared to traditional surgery, alongside a typically far shorter hospital stay and significantly lower risk of complications. There are 23 NHS England healthcare settings that have now adopted SSD. Dr Sal Khalid, Consultant Gastroenterologist at the Royal Oldham Hospital, said: "I'm very pleased with the outcomes the Speedboat Inject device is facilitating for our patients, allowing our advanced endoscopists to remove complex high-risk lesions and even early cancer without the patient requiring invasive surgical treatment. "Almost all bowel cancers start as a lesion, and so having the technology now available to us to cut deeper and more safely through the layers of the bowel when removing a lesion enables us to ensure that it's completely removed and reduce the chances of patients requiring an operation. "It's already clear that this will have a lasting effect, with the treatment reducing the chances of recurrence from 15% to 1% and potentially providing a cure for lesions containing early cancer without requiring operation. "Indeed, only three months into the new service we are already recording a reduction in the waiting lists not only across our endoscopy suites but, perhaps most importantly, in terms of those waiting for the surgical treatment of more invasive cancers. "The best part about the new service is being able to call a patient a few days later and tell them that they have had a curative outcome - that the lesion has been removed with the necessary margins not to have to worry about it anymore. That was rarely the case before we introduced Speedboat Inject and the advanced energy. " The establishment of this service will help us maintain our status as one of the leading advanced endoscopy services in the country and help us move towards our goal of prevention, early detection, and treatment of bowel cancer." Dr Khalid has now completed over 15 procedures using the Speedboat Inject device. Out of the first 10 cases, two were confirmed as cancers and three as showing features of high grade dysplasia, suggesting lesions very close to turning into a cancer. All of these lesions were successfully removed completely through an SSD procedure using Creo's advanced energy device. What next? -- SSD will become Royal Oldham's treatment of choice for high-risk polyps suspected of containing early cancer. Hundreds of patients every year are expected to benefit from this treatment option. -- Royal Oldham plans to expand the service and increase the number of conditions it can treat using this equipment. This will involve training endoscopists to perform a wider array of procedures using CROMA and Speedboat. -- An expanded service will be supported by a dedicated multidisciplinary team involving experts from across all the relevant specialties, ensuring every patient gets the best treatment based on expert knowledge, with every decision supported by the most current medical evidence. -- Royal Oldham will also aim to offer training opportunities to help teach this advanced technique to a wider pool of doctors, including the establishment of training posts of Endoscopy Fellows who will receive dedicated training and experience of decision making and performing SSD procedures under direct supervision of Dr Sal Khalid and his team. Craig Gulliford, CEO of Creo Medical said: "Oldham provides a phenomenal model for what's possible when a hospital immediately recognises the potential of the device and implements the right pathways and resource to maximise its impact. "To know that there are 40 patients in and around Oldham who have already benefited from our technology and the excellent service provided by Dr Khalid and his team is incredibly gratifying, with the knock-on positive effects on waiting lists and hospital resources now well established. "To hear plans for the further expansion of the service is also excellent news and we look forward to supporting the hospital in every way we can." |
Posted at 20/6/2023 14:34 by someuwin The most likely candidate to buy CREO is Pentax Medical (part of Japanese giant Hoya).They bought 6% of CREO some time ago and put one of their men on the board. Their holding has diluted to less than 3% now so doesn't show up, but I believe they are still there and could pounce at any stage. Note also CREO Chief Commercial Officer David Woods' history... David Woods Chief Commercial Officer David joined Creo as CCO in August 2020, having previously sat on Creo’s Board as a Non-Executive Director. David provides leadership and strategic direction for Creo’s commercial divisions, overseeing all strategic global commercial activities. David is an industry veteran within the MedTech sector. His experience encompasses Gastroenterology, General and Orthopaedic Surgery, Pulmonology and Ear, Nose and Throat. Prior to joining Creo, David was the President and CEO of PENTAX Americas and M&A Director of Hoya Corporation, Pentax Life Care Division. David brings significant operating and commercial experience, market understanding and a proven track record of achievement to Creo. He has also previously sat on multiple MedTech boards over the years. He was awarded the American Society for Gastrointestinal Endoscopy President’s Award in 2010, recognising exceptional contributions to the society and its mission. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
